{"gene":"CEACAM1","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2014,"finding":"CEACAM1 forms a heterodimer with TIM-3 via their membrane-distal IgV-like N-terminal domains, both in cis (facilitating TIM-3 maturation and cell surface expression) and in trans (mediating inhibitory signaling); CEACAM1 is required for TIM-3 inhibitory function in T cells","method":"Biochemical co-immunoprecipitation, biophysical binding assays, X-ray crystallography, mouse adoptive transfer colitis model, T cell-specific CEACAM1 deletion/reconstitution","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — X-ray crystallography plus multiple biochemical methods plus in vivo genetic rescue in a single study","pmids":["25363763"],"is_preprint":false},{"year":2006,"finding":"CEACAM1 isoforms with long cytoplasmic domain inhibit T cell activation (proliferation, cytokine production, allogeneic reactivity) through ITIMs in the cytoplasmic domain that recruit SHP1; conditional T cell deletion of CEACAM1 enhances TCR-CD3 signaling","method":"CEACAM1 overexpression and conditional deletion in T cells, in vitro T cell assays, mouse models of delayed-type hypersensitivity and inflammatory bowel disease, ITIM mutagenesis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype plus ITIM mutagenesis and SHP1 dependence across multiple assays","pmids":["17081782"],"is_preprint":false},{"year":1995,"finding":"The cytoplasmic domain of CEACAM1 associates with pp60c-src; the recombinant cytoplasmic domain is both a substrate and binding partner of pp60c-src in vitro, and tyrosine-containing phosphopeptides from the cytoplasmic domain activate pp60c-src kinase activity","method":"Co-immunoprecipitation from granulocytes and HT29 cells, in vitro kinase assay with recombinant cytoplasmic domain","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution and co-IP from endogenous sources with orthogonal methods","pmids":["7478590"],"is_preprint":false},{"year":2001,"finding":"Phosphorylated Tyr488 of CEACAM1 binds the SH2 domain of Shc, sequestering Shc from the insulin receptor/Grb2 complex and down-regulating the Ras/MAP kinase mitogenesis pathway and PI3K/Akt pathway","method":"Co-immunoprecipitation in NIH 3T3 cells, GST pull-down assays, Shc SH2 domain overexpression rescue experiments, MAP kinase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — GST pull-down plus co-IP plus functional rescue with multiple pathway readouts","pmids":["11694516"],"is_preprint":false},{"year":2002,"finding":"CEACAM1 regulates insulin clearance in liver; phosphorylation of CEACAM1 on Ser503 is required for receptor-mediated insulin endocytosis and degradation; dominant-negative S503A mutant transgenic mice show impaired insulin clearance and insulin resistance","method":"Transgenic mouse overexpressing phosphorylation-defective S503A CEACAM1 mutant in liver (L-SACC1 model), metabolic phenotyping","journal":"Trends in endocrinology and metabolism: TEM","confidence":"High","confidence_rationale":"Tier 2 — in vivo site-directed mutagenesis with defined metabolic phenotype in transgenic model","pmids":["12128284"],"is_preprint":false},{"year":2001,"finding":"The cytoplasmic tail of CEACAM1 (BGPa) contains functional ITIMs; tyrosine Y459 within the ITIM is required for inhibitory signaling; CEACAM1 inhibitory signaling requires SHP-1 and SHP-2 phosphatases","method":"FcγRIIB-BGPa chimeric receptor expressed in DT40 B cells, calcium influx assays, Y459F mutagenesis, SHP-1/SHP-2 mutant DT40 cells","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus defined phosphatase-deficient cell lines with functional assay","pmids":["11493628"],"is_preprint":false},{"year":2008,"finding":"Bacterial engagement of CEACAM1 (via M. catarrhalis UspA1 or N. meningitidis Opa proteins) triggers tyrosine phosphorylation of CEACAM1 ITIMs, recruits SHP-1, and inhibits TLR2-initiated NF-κB signaling and PI3K-Akt pathway in pulmonary epithelial cells","method":"Bacterial infection of primary pulmonary epithelial cells, phosphorylation assays, SHP-1 recruitment assays, NF-κB and Akt pathway readouts","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays including pathway endpoint readouts with mechanistic detail in primary cells","pmids":["18836450"],"is_preprint":false},{"year":2012,"finding":"LPS-activated neutrophils form a complex of TLR4, phospho-Syk, and phospho-CEACAM1; this complex recruits SHP-1 via CEACAM1 ITIMs to inhibit IL-1β production by the inflammasome; ITIM mutation abolishes this regulation","method":"Co-immunoprecipitation, Ceacam1−/− neutrophils, in vivo bone marrow reconstitution with ITIM-mutant CEACAM1, Syk inhibitors, RNAi knockdown","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — complex reconstitution in vivo plus ITIM mutagenesis plus knockout rescue with multiple orthogonal methods","pmids":["22496641"],"is_preprint":false},{"year":2013,"finding":"CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolysis via trans-homophilic CEACAM1 interactions; co-engagement of NKG2D and CEACAM1 causes biochemical association of these receptors and CEACAM1-recruited SHP-1 dephosphorylates Vav1, blocking downstream cytolytic signaling","method":"NK cell cytotoxicity assays, co-immunoprecipitation, phosphorylation assays for Vav1, mouse and human NK cells with IL-2-induced CEACAM1 expression","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — receptor co-immunoprecipitation plus downstream signaling readout plus trans-interaction requirement established in both mouse and human NK cells","pmids":["23696226"],"is_preprint":false},{"year":2004,"finding":"CEACAM1 is a substrate of EGFR; upon phosphorylation, CEACAM1 reduces EGFR-mediated cell growth by binding to and sequestering Shc, uncoupling EGFR from the Ras/MAPK pathway","method":"Co-immunoprecipitation in transfected Cos-7 and MCF-7 cells, transgenic L-SACC1 mice with phosphorylation-defective CEACAM1 mutant, MAPK activity assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — co-IP plus in vivo transgenic model with mechanistic pathway dissection","pmids":["15467833"],"is_preprint":false},{"year":2005,"finding":"CEACAM1-L cytoplasmic domain directly binds filamin A; when co-expressed, CEACAM1-L and filamin A drastically reduce cell migration and scattering compared with either protein alone; this interaction reduces RalA binding to filamin A and decreases focal adhesion turnover","method":"Yeast two-hybrid screen, surface plasmon resonance, affinity precipitation, migration/scattering assays in melanoma cells, focal adhesion assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 — direct binding confirmed by SPR plus functional rescue experiments with mechanistic detail","pmids":["16291724"],"is_preprint":false},{"year":2005,"finding":"CEACAM1-mediated delay of spontaneous and Fas ligand-induced granulocyte apoptosis requires tyrosine phosphorylation of CEACAM1-L, its association with SHP-1, and activation of Erk1/2; caspase-3 is also involved","method":"DNA fragmentation assays, annexin V staining, CEACAM1-Fc constructs, CEACAM1-specific Fab fragments, co-immunoprecipitation, kinase activation assays in rat granulocytes","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays with mechanistic signaling detail in a single lab study","pmids":["15909305"],"is_preprint":false},{"year":2002,"finding":"Homotypic CEACAM1 interactions between melanoma cells and NK cells provide MHC class I-independent inhibition of NK cytotoxicity; inhibitory strength correlates with CEACAM1 expression levels","method":"NK cell cytotoxicity assays, redirected lysis experiments, CD66a transfectants of 721.221 cells, NK clones from melanoma patients","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — defined cellular phenotype with dose-response relationship, transfectant and patient-derived NK cell validation","pmids":["11884449"],"is_preprint":false},{"year":2011,"finding":"Tumor cell-associated CEACAM1 causes intracellular retention of NKG2D ligands in mouse and human tumor cells; CEACAM1-silenced tumor cells display more cell surface NKG2D ligands and greater sensitivity to NK cell-mediated cytolysis in vitro and rejection in vivo","method":"CEACAM1 silencing in tumor cells, flow cytometry for NKG2D ligand surface expression, NK cytotoxicity assays, in vivo tumor rejection","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — clean KD with defined molecular and cellular phenotypes in vitro and in vivo","pmids":["22143889"],"is_preprint":false},{"year":2018,"finding":"CEACAM1 is required for recruiting Lck into the TCR complex to form an efficient immunological synapse in CD8+ T cells; absence of CEACAM1 limits antiviral CD8+ T cell activation; anti-CEACAM1 antibody stabilizes Lck in the immunological synapse and prevents CD8+ T cell exhaustion","method":"LCMV infection model in Ceacam1−/− mice, immunological synapse imaging, Lck co-immunoprecipitation, anti-CEACAM1 antibody treatment, human virus-specific CD8+ T cell proliferation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus mechanistic co-IP plus antibody intervention replicated in mouse and human","pmids":["29967450"],"is_preprint":false},{"year":2015,"finding":"CEACAM1 promotes B cell survival via the BTK/Syk/NF-κB signaling axis; Ceacam1−/− mice have reduced B cell survival and fail to mount protective neutralizing antibody responses during cytopathic viral infection","method":"Ceacam1−/− mice, VSV infection model, flow cytometry for B cell survival, BTK/Syk/NF-κB pathway analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined survival pathway and in vivo infectious challenge","pmids":["25692415"],"is_preprint":false},{"year":2004,"finding":"CEACAM1 expression enhances melanoma cell invasion and migration in a manner dependent on Tyr-488 in the cytoplasmic domain and on αvβ3 integrin; integrin β3 induces CEACAM1 upregulation in melanocytic cells","method":"Stable CEACAM1 transfection in melanocytic/melanoma cells, invasion/migration assays, anti-CEACAM antibody blockade, RGD peptide inhibition, Tyr-488 mutagenesis","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis plus multiple functional assays plus antibody and peptide inhibition","pmids":["15509546"],"is_preprint":false},{"year":2008,"finding":"CEACAM1 negatively regulates platelet-collagen interactions via GPVI/FcR-γ-chain signaling; Ceacam1−/− platelets show enhanced collagen-mediated aggregation and granule secretion; SHP-1 recruitment through CEACAM1 ITIMs mediates this inhibitory function; ceacam1−/− mice form larger, more stable thrombi in vivo","method":"Ceacam1−/− mice, platelet aggregation assays, CRP-stimulation, intravital microscopy of FeCl3-injured mesenteric arterioles, GPVI depletion rescue, pulmonary thromboembolism model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean KO with multiple in vitro and in vivo functional assays and epistasis via GPVI depletion","pmids":["19008452"],"is_preprint":false},{"year":2014,"finding":"CEACAM1 long isoform (CEACAM1-4L) downregulates cell surface NKG2D ligands (MICA, ULBP2) by enhanced shedding, promoting immune escape; whereas CEACAM1-3S isoform upregulates NKG2D ligands and sensitizes melanoma cells to NK lysis — demonstrating isoform-specific immunomodulatory mechanisms","method":"Isoform-specific knockdown and overexpression in melanoma cells, flow cytometry for NKG2D ligand surface expression, NK cytotoxicity assays, in vivo xenograft model, patient survival analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific KD/OE with defined molecular phenotype but single lab","pmids":["25744717"],"is_preprint":false},{"year":2019,"finding":"Fusobacterium nucleatum binds and activates CEACAM1 via its surface protein CbpF (trimeric autotransporter adhesin), leading to inhibition of T and NK cell activities; CbpF-specific mutants abolish CEACAM1 binding and T cell inhibition","method":"F. nucleatum mutants lacking CbpF and other trimeric autotransporter adhesins, CEACAM1 binding assays, functional T cell and NK cell inhibition assays, anti-CEACAM1 N-domain antibody blocking","journal":"Oncoimmunology / Frontiers in cellular and infection microbiology","confidence":"High","confidence_rationale":"Tier 2 — specific bacterial mutants plus functional immune assays plus antibody blocking replicated across two studies","pmids":["31069151","34336716"],"is_preprint":false},{"year":2005,"finding":"DC-SIGN binds CEACAM1 on neutrophils via Lewis x glycan moieties specifically expressed on neutrophil-derived CEACAM1; both DC-SIGN-CEACAM1 and DC-SIGN-Mac-1 interactions are required to establish DC-neutrophil cellular contact","method":"CEACAM1 binding assays with DC-SIGN, fucosidase treatment, antibody blocking, co-culture DC-neutrophil interaction assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding plus fucosidase abrogation plus functional co-culture assay","pmids":["16246332"],"is_preprint":false},{"year":2004,"finding":"CEACAM1 N-glycans from human granulocytes carry Lewis x epitopes; MALDI-TOF MS and sequential exoglycosidase digestion characterized multiple Lewis x glycan structures with alpha(1-3,4) fucose linkages on CEACAM1","method":"Immunoaffinity purification of CEACAM1, Lewis x-specific antibody binding, fucosidase III treatment, MALDI-TOF MS with sequential exoglycosidase digestion","journal":"Glycobiology","confidence":"High","confidence_rationale":"Tier 1 — MS structural characterization plus enzymatic digestion validation","pmids":["15317738"],"is_preprint":false},{"year":2014,"finding":"CEACAM1 long isoform increases melanoma cell proliferation via upregulation of Sox-2; this effect requires the full-length long cytoplasmic tail and is not reversed by CEACAM1-blocking antibody, indicating it is not mediated by homophilic interactions","method":"CEACAM1 knockdown and overexpression of selective variants/truncation mutants, in vitro and in vivo proliferation assays, Sox-2 expression analysis, CEACAM1-blocking antibody treatment","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 — structure-function analysis with truncation mutants and downstream target identification","pmids":["24931667"],"is_preprint":false},{"year":2019,"finding":"CEACAM6 expressed on cancer cells inhibits T cell antitumor activity by binding CEACAM1 on activated T cells (trans heterophilic interaction); blocking CEACAM6 with antibody BAY 1834942 reactivates T cell responses","method":"Co-culture experiments with T cells and solid cancer cells, CEACAM6-CEACAM1 interaction assays, cytokine and killing assays, comparison with PD-1/PD-L1/TIM-3 checkpoint blockade","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 — blocking antibody plus functional T cell assays in co-culture establishing CEACAM6-CEACAM1 trans interaction requirement","pmids":["35141051"],"is_preprint":false},{"year":2002,"finding":"CEACAM1 clustering by surface ligation induces rapid tyrosine dephosphorylation, reduced association with SHP2, translocation to actin cytoskeleton, and activation of ERK1/2 MAPK in PC12 cells","method":"Antibody-induced CEACAM1 clustering, phosphorylation assays, co-immunoprecipitation with SHP2, detergent fractionation for cytoskeleton association, ERK1/2 activation assay","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal signaling assays in a single study","pmids":["12108545"],"is_preprint":false},{"year":2014,"finding":"Soluble CEACAM8 binds CEACAM1 on pulmonary epithelial cells and inhibits TLR2-dependent NF-κB signaling via CEACAM1 ITIM phosphorylation and SHP-1 recruitment, suppressing PI3K-Akt pathway activation","method":"Recombinant CEACAM8-Fc binding to CEACAM1-positive epithelial cells, TLR2 stimulation assays, ITIM phosphorylation assays, SHP-1 co-immunoprecipitation, Akt pathway readouts","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct heterophilic binding plus multiple signaling pathway assays; partially recapitulates earlier CEACAM1-SHP1 mechanism","pmids":["24743304"],"is_preprint":false},{"year":2019,"finding":"CEACAM1 regulates the LPS-driven IL-6 fever response through monocyte RP105 receptor signaling; CEACAM1 recruits SHP-1 to sequester phospho-VAV1 and β-actin from RP105, negatively regulating this pathway; Ceacam1−/− mice over-produce IL-6 in response to LPS","method":"Ceacam1−/− mice LPS challenge, in vitro monocyte stimulation, RP105 complex co-immunoprecipitation, SHP-1 recruitment assays, PET imaging with 64Cu-LPS","journal":"BMC immunology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mice with in vivo phenotype plus co-IP complex identification","pmids":["30674283"],"is_preprint":false},{"year":2023,"finding":"HIF-1α controls alternative splicing of CEACAM1 toward the short cytoplasmic isoform (Ceacam1-S) through transcriptional regulation of the Ptbp1 promoter; Ceacam1-S protects hepatocytes from hypoxia-induced loss of adhesion by repressing the ASK1/p-p38 cell death pathway","method":"Chromatin immunoprecipitation assays identifying HIF-1α binding to Ptbp1 promoter, luciferase reporter assays, adenoviral Ceacam1-S transfection in KO hepatocytes, morpholino-induced Ceacam1-S splicing, DMOG prolyl hydroxylase inhibitor treatment, in vitro and in vivo mouse models","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1 — ChIP-confirmed transcription factor binding plus functional reconstitution plus pharmacologic intervention with defined pathway readout","pmids":["37531413"],"is_preprint":false},{"year":2023,"finding":"The long cytoplasmic isoform of CEACAM1 (CC1-L) in neutrophils determines susceptibility to NETosis by regulating the S1P-S1PR2/S1PR3 axis and autophagy signaling; ablation of CC1-L aggravates hepatic ischemia-reperfusion injury by promoting NET formation","method":"Mouse OLT model with isoform-specific CC1-L ablation, NETosis assays, S1P-S1PR2/S1PR3 axis analysis, autophagy signaling assays, human liver transplant biopsy analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific genetic ablation in mouse OLT model with defined pathway and validated in human clinical samples","pmids":["36719377"],"is_preprint":false},{"year":1999,"finding":"CD66a (CEACAM1) and CD66b are the major galectin-3 receptors on human neutrophils; both proteins are stored in gelatinase and specific granules and mobilized to the cell surface upon activation","method":"Galectin-3-Sepharose affinity chromatography of neutrophil granule proteins, immunoblotting, lactose elution, subcellular fractionation, differentiated HL-60 cells lacking specific granules","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — affinity chromatography identification plus subcellular localization confirmed by granule fractionation","pmids":["10553088"],"is_preprint":false},{"year":2018,"finding":"CEACAM1 expression in hepatocytes protects against ischemia-reperfusion injury by suppressing ASK1/p-p38 upregulation, reducing ROS induction and HMGB1 translocation; CC1-deficient livers show augmented cold stress-triggered ASK1/p-p38 signaling","method":"CC1-KO mouse OLT model, ASK1 inhibition rescue, ROS and HMGB1 assays, bone marrow-derived macrophage co-culture, siRNA ASK1 silencing in hepatocyte cultures, human liver biopsy correlation","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus ASK1 inhibitor epistasis plus in vitro cell culture mechanistic validation plus human correlation","pmids":["32027621"],"is_preprint":false},{"year":2018,"finding":"CEACAM1 deficiency causes eNOS depalmitoylation and subcellular redistribution, altered endothelial glycocalyx (through repression of glycocalyx-degrading enzymes), increased leukocyte-endothelial adhesion, and age-dependent modulation of endothelial barrier function through β-catenin and caveolin-1 phosphorylation","method":"Ceacam1−/− mice, eNOS localization by immunofluorescence, glycocalyx assays, leukocyte adhesion assays, β-catenin/caveolin-1 phosphorylation Western blot, TNF-α stimulation","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse model with multiple molecular mechanism readouts but a single lab study","pmids":["29746166"],"is_preprint":false},{"year":2015,"finding":"Forced hepatic CEACAM1 overexpression in mice prevents high-fat diet-induced hyperinsulinemia, insulin resistance, and hepatic lipid accumulation partly by increasing hepatic β-fatty acid oxidation and energy expenditure","method":"Liver-specific inducible CEACAM1 expression (L-CC1) transgenic mice, high-fat diet metabolic challenge, glucose/insulin tolerance tests, fatty acid oxidation assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function transgenic model with defined metabolic phenotype and mechanistic pathway (β-oxidation)","pmids":["25972571"],"is_preprint":false},{"year":2018,"finding":"CEACAM1 or CEACAM5 expression in AZ-521 cells (which lack CEACAMs) restores H. pylori type IV secretion system-mediated CagA translocation and phosphorylation, identifying CEACAM1 as a T4SS receptor for CagA injection","method":"CEACAM1/CEACAM5/CEACAM6 transfection into AZ-521 cells, H. pylori infection, CagA translocation and phosphorylation assays, vinculin/cortactin dephosphorylation assays","journal":"Cellular microbiology","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function reconstitution with receptor specificity established (CEACAM1/5 but not 6) plus downstream effector validation","pmids":["30321907"],"is_preprint":false},{"year":1999,"finding":"Cross-linking of CEACAM1 on intestinal intraepithelial lymphocytes (iIEL) with mAbs recognizing the N domain inhibits anti-CD3-directed and LAK cytolytic activity; the N domain mediates inhibitory signaling","method":"Expression cloning identifying CEACAM1 as mAb antigen, Fc fusion protein binding studies, functional cytolysis inhibition assays with iIEL","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — expression cloning plus functional inhibition assay with domain identification","pmids":["10415036"],"is_preprint":false}],"current_model":"CEACAM1 is a multifunctional transmembrane glycoprotein that signals primarily through ITIM-mediated recruitment of SHP-1/SHP-2 phosphatases upon tyrosine phosphorylation of its long cytoplasmic domain, thereby inhibiting T cell, NK cell, neutrophil, platelet, and B cell activation; it also forms cis and trans heterodimers with TIM-3 to regulate T cell tolerance, associates with pp60c-src and recruits Lck into the immunological synapse, sequesters Shc to downregulate Ras/MAPK and PI3K/Akt mitogenic signaling downstream of insulin and EGF receptors, binds filamin A to modulate cell migration, regulates alternative splicing of its own isoforms through HIF-1α/Ptbp1 to protect against hepatic ischemia-reperfusion injury, and serves as a bacterial receptor (for Neisseria Opa proteins, H. pylori CagA T4SS, and Fusobacterium CbpF) that pathogens exploit for immune evasion."},"narrative":{"teleology":[{"year":1995,"claim":"Identifying the first intracellular signaling partner of CEACAM1 established that it is a substrate and activator of pp60c-src, positioning it as a phosphotyrosine-based signaling receptor rather than a passive adhesion molecule.","evidence":"Co-immunoprecipitation from granulocytes/HT29 cells and in vitro kinase assays with recombinant cytoplasmic domain","pmids":["7478590"],"confidence":"High","gaps":["Identity of the kinase(s) responsible for CEACAM1 phosphorylation in vivo not resolved","Functional consequence of Src activation by CEACAM1 not determined"]},{"year":1999,"claim":"Demonstrating that cross-linking the CEACAM1 N-domain inhibits cytolytic activity of intestinal intraepithelial lymphocytes established that CEACAM1 functions as an inhibitory receptor in the immune system, with domain-level specificity.","evidence":"Expression cloning, Fc fusion binding, and functional cytolysis inhibition assays with iIEL","pmids":["10415036"],"confidence":"Medium","gaps":["Downstream signaling mechanism of inhibition not identified","Whether ITIM phosphatase recruitment mediates the effect was not tested"]},{"year":2001,"claim":"Identification of functional ITIMs in the cytoplasmic tail and demonstration that SHP-1/SHP-2 are the required effector phosphatases provided the core molecular mechanism of CEACAM1 inhibitory signaling, while parallel work showed phospho-Tyr488 sequesters Shc to attenuate Ras/MAPK and PI3K/Akt pathways downstream of insulin receptor.","evidence":"FcγRIIB-CEACAM1 chimeras in DT40 B cells with SHP-1/SHP-2-deficient lines and Y459F mutagenesis; GST pull-downs and co-IP in NIH 3T3 cells with MAPK activity rescue","pmids":["11493628","11694516"],"confidence":"High","gaps":["Whether SHP-1 vs SHP-2 has non-redundant roles in different cell types was unclear","Structural basis of ITIM-SHP interaction not determined"]},{"year":2002,"claim":"Demonstrating that trans-homophilic CEACAM1 engagement inhibits NK cytotoxicity independently of MHC class I revealed a new immune evasion axis; concurrently, Ser503 phosphorylation was shown to be required for hepatic insulin clearance, establishing CEACAM1 as a metabolic regulator.","evidence":"NK redirected lysis assays with CEACAM1 transfectants; L-SACC1 transgenic mice with S503A mutant metabolic phenotyping","pmids":["11884449","12128284"],"confidence":"High","gaps":["Molecular link between Ser503 phosphorylation and receptor-mediated endocytosis machinery not identified","Ligand on tumor cells engaging CEACAM1 trans-homophilic interaction not fully characterized"]},{"year":2004,"claim":"Showing CEACAM1 is an EGFR substrate that sequesters Shc to uncouple EGFR from MAPK signaling unified the Shc-sequestration mechanism across receptor tyrosine kinases, while Tyr488-dependent enhancement of melanoma invasion revealed context-dependent pro-migratory roles.","evidence":"Co-IP in Cos-7/MCF-7 cells plus L-SACC1 transgenic MAPK assays; CEACAM1 transfection in melanoma cells with Y488 mutagenesis and integrin blocking","pmids":["15467833","15509546"],"confidence":"High","gaps":["How the same Tyr488-Shc interaction mediates growth inhibition in epithelial cells but invasion in melanoma was not reconciled","Integrin β3–CEACAM1 crosstalk mechanism not elucidated"]},{"year":2005,"claim":"Direct binding of CEACAM1-L to filamin A established a structural link to the actin cytoskeleton, explaining how CEACAM1 reduces cell migration by displacing RalA from filamin A and decreasing focal adhesion turnover.","evidence":"Yeast two-hybrid, SPR, affinity precipitation, and migration/scattering assays in melanoma cells","pmids":["16291724"],"confidence":"High","gaps":["Whether filamin A interaction is regulated by CEACAM1 phosphorylation state was not tested","In vivo relevance of the CEACAM1–filamin A complex not demonstrated"]},{"year":2006,"claim":"Conditional T cell-specific deletion of CEACAM1 established it as a bona fide T cell inhibitory receptor in vivo, with ITIM-dependent SHP-1 recruitment required for suppression of TCR-CD3 signaling, proliferation, and cytokine production.","evidence":"Conditional KO T cells, in vitro T cell assays, mouse DTH and IBD models, ITIM mutagenesis","pmids":["17081782"],"confidence":"High","gaps":["Relative contributions of SHP-1 vs SHP-2 in T cell inhibition not delineated","Whether CEACAM1 inhibitory function is ligand-dependent or constitutive in T cells not resolved"]},{"year":2008,"claim":"Bacterial exploitation of CEACAM1 was mechanistically defined: Neisseria/Moraxella Opa/UspA1 engagement triggers ITIM phosphorylation and SHP-1 recruitment to suppress TLR2-NF-κB and PI3K-Akt signaling, while CEACAM1 was separately shown to be an ITIM-dependent inhibitor of platelet GPVI-collagen signaling governing thrombus formation in vivo.","evidence":"Primary pulmonary epithelial infection with bacterial mutants and pathway readouts; Ceacam1−/− platelet aggregation, intravital microscopy, and GPVI depletion rescue","pmids":["18836450","19008452"],"confidence":"High","gaps":["Whether bacterial engagement activates a distinct downstream program beyond canonical ITIM-SHP1 not known","Structural basis of Opa–CEACAM1 N-domain interaction not resolved at atomic level"]},{"year":2012,"claim":"Discovery that CEACAM1 forms a ternary complex with TLR4 and phospho-Syk in neutrophils to recruit SHP-1 and suppress inflammasome-driven IL-1β production expanded its inhibitory role to innate immune danger signaling.","evidence":"Co-IP in Ceacam1−/− neutrophils, in vivo bone marrow reconstitution with ITIM-mutant CEACAM1, Syk inhibitors, RNAi","pmids":["22496641"],"confidence":"High","gaps":["Whether CEACAM1 directly interacts with NLRP3 inflammasome components not tested","Upstream signal triggering CEACAM1–Syk association not identified"]},{"year":2013,"claim":"The NK cell inhibitory mechanism was refined: trans-homophilic CEACAM1 ligation recruits SHP-1 to dephosphorylate Vav1, directly blocking NKG2D cytolytic signaling, identifying a specific phosphatase substrate mediating immune evasion.","evidence":"Co-IP and phospho-Vav1 assays in IL-2-activated mouse and human NK cells plus cytotoxicity assays","pmids":["23696226"],"confidence":"High","gaps":["Whether other activating receptor pathways beyond NKG2D are similarly regulated not tested","Structural determinants of CEACAM1–NKG2D co-association not defined"]},{"year":2014,"claim":"Structural and functional evidence that CEACAM1 heterodimerizes with TIM-3 via N-terminal IgV domains in both cis and trans, and is required for TIM-3 maturation, surface expression, and inhibitory function, established a new paradigm of immune checkpoint cooperativity; simultaneously, isoform-specific regulation of NKG2D ligand shedding was demonstrated.","evidence":"X-ray crystallography, co-IP, biophysical binding, T cell-specific CEACAM1 KO/reconstitution, adoptive transfer colitis; isoform-specific KD/OE with NK cytotoxicity and xenograft","pmids":["25363763","25744717"],"confidence":"High","gaps":["Structural basis of cis vs trans dimer selectivity not fully resolved","Signaling events downstream of CEACAM1–TIM-3 trans ligation not characterized"]},{"year":2015,"claim":"CEACAM1 was shown to promote B cell survival via BTK/Syk/NF-κB signaling and to be required for protective antibody responses during viral infection, establishing a pro-survival function distinct from its canonical inhibitory role.","evidence":"Ceacam1−/− mice, VSV infection, B cell survival flow cytometry, BTK/Syk/NF-κB pathway analysis","pmids":["25692415"],"confidence":"High","gaps":["Whether CEACAM1 directly engages BTK/Syk or acts indirectly not determined","Mechanism reconciling pro-survival B cell function with inhibitory signaling in other lymphocytes not established"]},{"year":2018,"claim":"CEACAM1 was found to recruit Lck into the immunological synapse of CD8+ T cells, with its absence limiting antiviral T cell activation and antibody-mediated CEACAM1 stabilization preventing exhaustion—revealing a co-stimulatory dimension alongside its inhibitory functions; separately, CEACAM1 was identified as a receptor for H. pylori CagA T4SS injection.","evidence":"LCMV infection in Ceacam1−/− mice, Lck co-IP, synapse imaging, anti-CEACAM1 antibody in mouse/human; CEACAM1 transfection into AZ-521 cells restoring CagA translocation","pmids":["29967450","30321907"],"confidence":"High","gaps":["How CEACAM1 simultaneously recruits Lck (activating) and SHP-1 (inhibitory) is mechanistically unresolved","Whether CagA translocation requires CEACAM1 ITIM signaling not tested"]},{"year":2019,"claim":"Fusobacterium nucleatum CbpF was identified as a CEACAM1 ligand that triggers T and NK cell inhibition, extending the bacterial immune evasion paradigm to a tumor-associated pathogen; CEACAM1 was also shown to regulate monocyte IL-6 fever response via SHP-1 sequestration of VAV1 from RP105.","evidence":"F. nucleatum CbpF mutants with CEACAM1 binding/T cell assays; Ceacam1−/− mice LPS challenge with RP105 co-IP","pmids":["31069151","34336716","30674283"],"confidence":"High","gaps":["Whether CbpF-CEACAM1 interaction contributes to Fusobacterium-associated colorectal cancer immune evasion in vivo not demonstrated","RP105–CEACAM1 interaction awaits structural characterization"]},{"year":2023,"claim":"Isoform-specific functions were mechanistically grounded: HIF-1α transcriptionally induces Ptbp1 to splice CEACAM1 toward the short isoform, which protects hepatocytes from ASK1/p-p38 death signaling during hypoxia; conversely, the long isoform in neutrophils restrains NETosis via S1P–S1PR2/3 and autophagy, with its ablation worsening hepatic ischemia-reperfusion injury.","evidence":"ChIP for HIF-1α on Ptbp1 promoter, adenoviral Ceacam1-S reconstitution, morpholino splicing, DMOG treatment; isoform-specific CC1-L ablation in mouse OLT with NETosis/S1P pathway assays and human biopsy validation","pmids":["37531413","36719377"],"confidence":"High","gaps":["Whether Ptbp1-mediated splicing regulation occurs in non-hepatic tissues not tested","Direct molecular target of CEACAM1-S that represses ASK1 not identified","How CEACAM1-L regulates S1P receptor balance mechanistically remains unclear"]},{"year":null,"claim":"The mechanism by which CEACAM1 simultaneously mediates inhibitory (SHP-1/SHP-2 recruitment) and activating (Lck recruitment, B cell survival via BTK/Syk) functions in different immune contexts, and how isoform balance is dynamically regulated beyond hepatic ischemia, remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model reconciling inhibitory vs co-stimulatory CEACAM1 signaling across cell types","Structural basis for isoform-specific partner selectivity not determined","In vivo therapeutic window for checkpoint blockade of CEACAM1 vs CEACAM1–TIM-3 axis not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,6,7,8,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,10,14]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[6,19,33]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,12,14,17,20]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[29]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[10,24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,5,6,7,8,14,15,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,9,17,24]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[17]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,12,20,23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,32]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,27,30]}],"complexes":["CEACAM1–TIM-3 heterodimer","CEACAM1–TLR4–Syk complex","CEACAM1–filamin A complex"],"partners":["TIM-3","SHP-1","SHP-2","SRC","LCK","FLNA","SHC1","CEACAM6"],"other_free_text":[]},"mechanistic_narrative":"CEACAM1 is a multifunctional immunoregulatory transmembrane glycoprotein that broadly dampens activation signals in T cells, NK cells, neutrophils, platelets, and B cells while simultaneously modulating hepatic insulin clearance, cell migration, and pathogen entry. Its inhibitory signaling proceeds through ITIM-dependent recruitment of SHP-1 and SHP-2 phosphatases upon tyrosine phosphorylation of the long cytoplasmic domain (Tyr459/Tyr488), which dephosphorylates downstream effectors such as Vav1, uncouples Shc from receptor tyrosine kinases (insulin receptor, EGFR) to attenuate Ras/MAPK and PI3K/Akt signaling, and suppresses TLR-initiated NF-κB activation [PMID:11493628, PMID:11694516, PMID:18836450, PMID:23696226]. CEACAM1 forms obligate cis and trans heterodimers with TIM-3 through its N-terminal IgV domain, is required for TIM-3 surface expression and T cell inhibitory function, and recruits Lck into the immunological synapse of CD8⁺ T cells, positioning it as a dual checkpoint regulator [PMID:25363763, PMID:29967450]. The N-terminal domain also serves as a receptor exploited by bacterial adhesins—Neisseria Opa proteins, H. pylori CagA type IV secretion system, and Fusobacterium nucleatum CbpF—to trigger ITIM-mediated immune suppression or facilitate virulence factor injection [PMID:18836450, PMID:30321907, PMID:31069151]. Isoform-specific functions are regulated by HIF-1α/Ptbp1-controlled alternative splicing: the short isoform protects hepatocytes from hypoxia-induced ASK1/p-p38 death signaling, while the long isoform in neutrophils restrains NETosis via S1P receptor signaling, collectively governing hepatic ischemia-reperfusion injury outcomes [PMID:37531413, PMID:36719377]."},"prefetch_data":{"uniprot":{"accession":"P13688","full_name":"Cell adhesion molecule CEACAM1","aliases":["Biliary glycoprotein 1","BGP-1","Carcinoembryonic antigen-related cell adhesion molecule 1","CEA cell adhesion molecule 1"],"length_aa":526,"mass_kda":57.6,"function":"Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Plays a role as coinhibitory receptor in immune response, insulin action and also functions as an activator during angiogenesis (PubMed:18424730, PubMed:23696226, PubMed:25363763). Its coinhibitory receptor function is phosphorylation- and PTPN6 -dependent, which in turn, suppress signal transduction of associated receptors by dephosphorylation of their downstream effectors. Plays a role in immune response, of T cells, natural killer (NK) and neutrophils (PubMed:18424730, PubMed:23696226). Upon TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by blocking granule exocytosis by mediating homophilic binding to adjacent cells, allowing interaction with and phosphorylation by LCK and interaction with the TCR/CD3 complex which recruits PTPN6 resulting in dephosphorylation of CD247 and ZAP70 (PubMed:18424730). Also inhibits T cell proliferation and cytokine production through inhibition of JNK cascade and plays a crucial role in regulating autoimmunity and anti-tumor immunity by inhibiting T cell through its interaction with HAVCR2 (PubMed:25363763). Upon natural killer (NK) cells activation, inhibit KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-homophilic interactions with CEACAM1 on the target cell and lead to cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment and then VAV1 dephosphorylation (PubMed:23696226). Upon neutrophils activation negatively regulates IL1B production by recruiting PTPN6 to a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome. Down-regulates neutrophil production by acting as a coinhibitory receptor for CSF3R by down-regulating the CSF3R-STAT3 pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By similarity). Also regulates insulin action by promoting INS clearance and regulating lipogenesis in liver through regulating insulin signaling (By similarity). Upon INS stimulation, undergoes phosphorylation by INSR leading to INS clearance by increasing receptor-mediated insulin endocytosis. This inernalization promotes interaction with FASN leading to receptor-mediated insulin degradation and to reduction of FASN activity leading to negative regulation of fatty acid synthesis. INSR-mediated phosphorylation also provokes a down-regulation of cell proliferation through SHC1 interaction resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and phosphatidylinositol 3-kinase pathways (By similarity). Functions as activator in angiogenesis by promoting blood vessel remodeling through endothelial cell differentiation and migration and in arteriogenesis by increasing the number of collateral arteries and collateral vessel calibers after ischemia. Also regulates vascular permeability through the VEGFR2 signaling pathway resulting in control of nitric oxide production (By similarity). Down-regulates cell growth in response to EGF through its interaction with SHC1 that mediates interaction with EGFR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Negatively regulates platelet aggregation by decreasing platelet adhesion on type I collagen through the GPVI-FcRgamma complex (By similarity). Inhibits cell migration and cell scattering through interaction with FLNA; interferes with the interaction of FLNA with RALA (PubMed:16291724). Mediates bile acid transport activity in a phosphorylation dependent manner (By similarity). Negatively regulates osteoclastogenesis (By similarity) Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Promotes populations of T cells regulating IgA production and secretion associated with control of the commensal microbiota and resistance to enteropathogens (By similarity)","subcellular_location":"Cell projection, microvillus membrane; Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/P13688/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CEACAM1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CEACAM1","total_profiled":1310},"omim":[{"mim_id":"619160","title":"CEA CELL ADHESION MOLECULE 7; CEACAM7","url":"https://www.omim.org/entry/619160"},{"mim_id":"615747","title":"CEA CELL ADHESION MOLECULE 8; CEACAM8","url":"https://www.omim.org/entry/615747"},{"mim_id":"611519","title":"POLYMERASE DELTA-INTERACTING PROTEIN 2; POLDIP2","url":"https://www.omim.org/entry/611519"},{"mim_id":"609142","title":"CEA CELL ADHESION MOLECULE 3; CEACAM3","url":"https://www.omim.org/entry/609142"},{"mim_id":"608160","title":"SRY-BOX 9; SOX9","url":"https://www.omim.org/entry/608160"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":230.9}],"url":"https://www.proteinatlas.org/search/CEACAM1"},"hgnc":{"alias_symbol":["BGP1","CD66a"],"prev_symbol":["BGP"]},"alphafold":{"accession":"P13688","domains":[{"cath_id":"2.60.40.10","chopping":"38-142","consensus_level":"high","plddt":95.7179,"start":38,"end":142},{"cath_id":"2.60.40.10","chopping":"149-232","consensus_level":"high","plddt":94.0095,"start":149,"end":232},{"cath_id":"2.60.40.10","chopping":"242-319","consensus_level":"high","plddt":95.4794,"start":242,"end":319},{"cath_id":"2.60.40.10","chopping":"330-416","consensus_level":"high","plddt":91.1815,"start":330,"end":416}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13688","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13688-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13688-F1-predicted_aligned_error_v6.png","plddt_mean":81.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CEACAM1","jax_strain_url":"https://www.jax.org/strain/search?query=CEACAM1"},"sequence":{"accession":"P13688","fasta_url":"https://rest.uniprot.org/uniprotkb/P13688.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13688/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13688"}},"corpus_meta":[{"pmid":"25363763","id":"PMC_25363763","title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25363763","citation_count":583,"is_preprint":false},{"pmid":"8543780","id":"PMC_8543780","title":"CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues.","date":"1996","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/8543780","citation_count":169,"is_preprint":false},{"pmid":"11884449","id":"PMC_11884449","title":"CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11884449","citation_count":145,"is_preprint":false},{"pmid":"31069151","id":"PMC_31069151","title":"Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1.","date":"2019","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31069151","citation_count":134,"is_preprint":false},{"pmid":"8699114","id":"PMC_8699114","title":"CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils.","date":"1996","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/8699114","citation_count":120,"is_preprint":false},{"pmid":"17081782","id":"PMC_17081782","title":"SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17081782","citation_count":117,"is_preprint":false},{"pmid":"7478590","id":"PMC_7478590","title":"Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7478590","citation_count":114,"is_preprint":false},{"pmid":"12128284","id":"PMC_12128284","title":"Regulation of insulin action by CEACAM1.","date":"2002","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/12128284","citation_count":106,"is_preprint":false},{"pmid":"15509546","id":"PMC_15509546","title":"CEACAM1 enhances invasion and migration of melanocytic and melanoma cells.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15509546","citation_count":104,"is_preprint":false},{"pmid":"32221015","id":"PMC_32221015","title":"EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32221015","citation_count":103,"is_preprint":false},{"pmid":"18836450","id":"PMC_18836450","title":"CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells.","date":"2008","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18836450","citation_count":101,"is_preprint":false},{"pmid":"33367783","id":"PMC_33367783","title":"Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes.","date":"2021","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33367783","citation_count":100,"is_preprint":false},{"pmid":"31604530","id":"PMC_31604530","title":"CEACAM1 structure and function in immunity and its therapeutic implications.","date":"2019","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31604530","citation_count":93,"is_preprint":false},{"pmid":"10553088","id":"PMC_10553088","title":"Identification of CD66a and CD66b as the major galectin-3 receptor candidates in human neutrophils.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10553088","citation_count":92,"is_preprint":false},{"pmid":"25489988","id":"PMC_25489988","title":"The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25489988","citation_count":91,"is_preprint":false},{"pmid":"10415036","id":"PMC_10415036","title":"Regulation of human intestinal intraepithelial lymphocyte cytolytic function by biliary glycoprotein (CD66a).","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10415036","citation_count":79,"is_preprint":false},{"pmid":"16246332","id":"PMC_16246332","title":"Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/16246332","citation_count":79,"is_preprint":false},{"pmid":"9626043","id":"PMC_9626043","title":"Dysregulated expression of CD66a (BGP, C-CAM), an adhesion molecule of the CEA family, in endometrial cancer.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9626043","citation_count":78,"is_preprint":false},{"pmid":"15909305","id":"PMC_15909305","title":"CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15909305","citation_count":74,"is_preprint":false},{"pmid":"10419049","id":"PMC_10419049","title":"Tumor-suppressive activity of CD66a in prostate cancer.","date":"1999","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/10419049","citation_count":74,"is_preprint":false},{"pmid":"22496641","id":"PMC_22496641","title":"CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22496641","citation_count":72,"is_preprint":false},{"pmid":"11493628","id":"PMC_11493628","title":"Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals.","date":"2001","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11493628","citation_count":66,"is_preprint":false},{"pmid":"15972507","id":"PMC_15972507","title":"Neisseria gonorrhoeae kills carcinoembryonic antigen-related cellular adhesion molecule 1 (CD66a)-expressing human B cells and inhibits antibody production.","date":"2005","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15972507","citation_count":64,"is_preprint":false},{"pmid":"19008452","id":"PMC_19008452","title":"CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19008452","citation_count":64,"is_preprint":false},{"pmid":"21413011","id":"PMC_21413011","title":"Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21413011","citation_count":64,"is_preprint":false},{"pmid":"22143889","id":"PMC_22143889","title":"CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22143889","citation_count":60,"is_preprint":false},{"pmid":"9858884","id":"PMC_9858884","title":"Expression of biliary glycoprotein (CD66a) in normal and malignant breast epithelial cells.","date":"1998","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9858884","citation_count":58,"is_preprint":false},{"pmid":"11694516","id":"PMC_11694516","title":"Shc and CEACAM1 interact to regulate the mitogenic action of insulin.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11694516","citation_count":58,"is_preprint":false},{"pmid":"15467833","id":"PMC_15467833","title":"CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15467833","citation_count":57,"is_preprint":false},{"pmid":"12832451","id":"PMC_12832451","title":"CEACAM1 is a potent regulator of B cell receptor complex-induced activation.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12832451","citation_count":56,"is_preprint":false},{"pmid":"19931551","id":"PMC_19931551","title":"BGP-15 inhibits caspase-independent programmed cell death in acetaminophen-induced liver injury.","date":"2009","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19931551","citation_count":55,"is_preprint":false},{"pmid":"16622242","id":"PMC_16622242","title":"Bgp, a secreted glycosaminoglycan-binding protein of Borrelia burgdorferi strain N40, displays nucleosidase activity and is not essential for infection of immunodeficient mice.","date":"2006","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16622242","citation_count":54,"is_preprint":false},{"pmid":"2402439","id":"PMC_2402439","title":"Properties of BGP1, a poly(dG)-binding protein from chicken erythrocytes.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2402439","citation_count":52,"is_preprint":false},{"pmid":"25972571","id":"PMC_25972571","title":"Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25972571","citation_count":52,"is_preprint":false},{"pmid":"34336716","id":"PMC_34336716","title":"Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34336716","citation_count":52,"is_preprint":false},{"pmid":"32027621","id":"PMC_32027621","title":"Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32027621","citation_count":51,"is_preprint":false},{"pmid":"22350755","id":"PMC_22350755","title":"BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.","date":"2012","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22350755","citation_count":49,"is_preprint":false},{"pmid":"30314283","id":"PMC_30314283","title":"CEACAM1 in Liver Injury, Metabolic and Immune Regulation.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30314283","citation_count":48,"is_preprint":false},{"pmid":"24743304","id":"PMC_24743304","title":"Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune responses.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24743304","citation_count":48,"is_preprint":false},{"pmid":"23696226","id":"PMC_23696226","title":"CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23696226","citation_count":48,"is_preprint":false},{"pmid":"30719234","id":"PMC_30719234","title":"Fusobacterium spp. target human CEACAM1 via the trimeric autotransporter adhesin CbpF.","date":"2019","source":"Journal of oral microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30719234","citation_count":48,"is_preprint":false},{"pmid":"21569294","id":"PMC_21569294","title":"The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes.","date":"2011","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21569294","citation_count":47,"is_preprint":false},{"pmid":"10751340","id":"PMC_10751340","title":"The adhesion molecule CEACAM1 (CD66a, C-CAM, BGP) is specifically expressed by the extravillous intermediate trophoblast.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10751340","citation_count":46,"is_preprint":false},{"pmid":"29967450","id":"PMC_29967450","title":"CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29967450","citation_count":46,"is_preprint":false},{"pmid":"11009093","id":"PMC_11009093","title":"Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11009093","citation_count":45,"is_preprint":false},{"pmid":"15159468","id":"PMC_15159468","title":"Bilateral generalized polymicrogyria (BGP): a distinct syndrome of cortical malformation.","date":"2004","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15159468","citation_count":45,"is_preprint":false},{"pmid":"17057197","id":"PMC_17057197","title":"Role of CEACAM1 as a regulator of T cells.","date":"2006","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17057197","citation_count":44,"is_preprint":false},{"pmid":"8018919","id":"PMC_8018919","title":"CD66 identifies the biliary glycoprotein (BGP) adhesion molecule: cloning, expression, and adhesion functions of the BGPc splice variant.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8018919","citation_count":44,"is_preprint":false},{"pmid":"25692415","id":"PMC_25692415","title":"CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25692415","citation_count":43,"is_preprint":false},{"pmid":"15476270","id":"PMC_15476270","title":"The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15476270","citation_count":43,"is_preprint":false},{"pmid":"36719377","id":"PMC_36719377","title":"Neutrophil CEACAM1 determines susceptibility to NETosis by regulating the S1PR2/S1PR3 axis in liver transplantation.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36719377","citation_count":42,"is_preprint":false},{"pmid":"16291724","id":"PMC_16291724","title":"CEACAM1 functionally interacts with filamin A and exerts a dual role in the regulation of cell migration.","date":"2005","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/16291724","citation_count":42,"is_preprint":false},{"pmid":"15317738","id":"PMC_15317738","title":"Identification of Lewis x structures of the cell adhesion molecule CEACAM1 from human granulocytes.","date":"2004","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15317738","citation_count":40,"is_preprint":false},{"pmid":"24258517","id":"PMC_24258517","title":"CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).","date":"2013","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24258517","citation_count":36,"is_preprint":false},{"pmid":"38677623","id":"PMC_38677623","title":"BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy.","date":"2024","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38677623","citation_count":36,"is_preprint":false},{"pmid":"35141051","id":"PMC_35141051","title":"T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.","date":"2021","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/35141051","citation_count":36,"is_preprint":false},{"pmid":"30321907","id":"PMC_30321907","title":"Expression of CEACAM1 or CEACAM5 in AZ-521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori.","date":"2018","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30321907","citation_count":35,"is_preprint":false},{"pmid":"30871206","id":"PMC_30871206","title":"Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30871206","citation_count":35,"is_preprint":false},{"pmid":"20404914","id":"PMC_20404914","title":"Generation of human CEACAM1 transgenic mice and binding of Neisseria Opa protein to their neutrophils.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20404914","citation_count":35,"is_preprint":false},{"pmid":"24931667","id":"PMC_24931667","title":"CEACAM1 promotes melanoma cell growth through Sox-2.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24931667","citation_count":33,"is_preprint":false},{"pmid":"27695943","id":"PMC_27695943","title":"The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis.","date":"2016","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27695943","citation_count":32,"is_preprint":false},{"pmid":"30406153","id":"PMC_30406153","title":"On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30406153","citation_count":32,"is_preprint":false},{"pmid":"15259011","id":"PMC_15259011","title":"Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15259011","citation_count":32,"is_preprint":false},{"pmid":"9250164","id":"PMC_9250164","title":"Dysregulation of carcinoembryonic antigen group members CGM2, CD66a (biliary glycoprotein), and nonspecific cross-reacting antigen in colorectal carcinomas. Comparative analysis by northern blot and in situ hybridization.","date":"1997","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9250164","citation_count":31,"is_preprint":false},{"pmid":"35470423","id":"PMC_35470423","title":"TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35470423","citation_count":31,"is_preprint":false},{"pmid":"28184213","id":"PMC_28184213","title":"Loss of Hepatic CEACAM1: A Unifying Mechanism Linking Insulin Resistance to Obesity and Non-Alcoholic Fatty Liver Disease.","date":"2017","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28184213","citation_count":31,"is_preprint":false},{"pmid":"29746166","id":"PMC_29746166","title":"Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29746166","citation_count":31,"is_preprint":false},{"pmid":"8481830","id":"PMC_8481830","title":"Serum levels of bone Gla protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long-term octreotide treatment.","date":"1993","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/8481830","citation_count":30,"is_preprint":false},{"pmid":"22322357","id":"PMC_22322357","title":"The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics.","date":"2012","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/22322357","citation_count":29,"is_preprint":false},{"pmid":"2786438","id":"PMC_2786438","title":"Bone GLA protein (BGP) levels and bone turnover in rheumatoid arthritis.","date":"1989","source":"British journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/2786438","citation_count":29,"is_preprint":false},{"pmid":"26885752","id":"PMC_26885752","title":"SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26885752","citation_count":28,"is_preprint":false},{"pmid":"32222966","id":"PMC_32222966","title":"TIM-3 and CEACAM1 do not interact in cis and in trans.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32222966","citation_count":27,"is_preprint":false},{"pmid":"15501754","id":"PMC_15501754","title":"Extracellular secretion of the Borrelia burgdorferi Oms28 porin and Bgp, a glycosaminoglycan binding protein.","date":"2004","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15501754","citation_count":26,"is_preprint":false},{"pmid":"30674283","id":"PMC_30674283","title":"CEACAM1 regulates the IL-6 mediated fever response to LPS through the RP105 receptor in murine monocytes.","date":"2019","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30674283","citation_count":26,"is_preprint":false},{"pmid":"25744717","id":"PMC_25744717","title":"CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25744717","citation_count":25,"is_preprint":false},{"pmid":"2135297","id":"PMC_2135297","title":"Influence of sex, age, and menopause in serum osteocalcin (BGP) levels.","date":"1990","source":"Klinische Wochenschrift","url":"https://pubmed.ncbi.nlm.nih.gov/2135297","citation_count":24,"is_preprint":false},{"pmid":"30089785","id":"PMC_30089785","title":"CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30089785","citation_count":24,"is_preprint":false},{"pmid":"35403834","id":"PMC_35403834","title":"A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35403834","citation_count":23,"is_preprint":false},{"pmid":"37531413","id":"PMC_37531413","title":"Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans.","date":"2023","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37531413","citation_count":22,"is_preprint":false},{"pmid":"8609714","id":"PMC_8609714","title":"CD49f (alpha 6 integrin) and CD66a (BGP) are specifically induced by retinoids during human monocytic differentiation.","date":"1995","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8609714","citation_count":21,"is_preprint":false},{"pmid":"26341981","id":"PMC_26341981","title":"Down-regulation of CEACAM1 in breast cancer.","date":"2015","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/26341981","citation_count":21,"is_preprint":false},{"pmid":"29486474","id":"PMC_29486474","title":"Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29486474","citation_count":21,"is_preprint":false},{"pmid":"33564362","id":"PMC_33564362","title":"BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/33564362","citation_count":21,"is_preprint":false},{"pmid":"22196267","id":"PMC_22196267","title":"CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.","date":"2012","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22196267","citation_count":21,"is_preprint":false},{"pmid":"21050451","id":"PMC_21050451","title":"Regulation of CEACAM1 transcription in human breast epithelial cells.","date":"2010","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21050451","citation_count":20,"is_preprint":false},{"pmid":"2208702","id":"PMC_2208702","title":"Measurement of serum bone gla-protein (BGP) in humans with an ovine BGP-based radioimmunoassay.","date":"1990","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2208702","citation_count":18,"is_preprint":false},{"pmid":"1864560","id":"PMC_1864560","title":"Serum bone Gla protein (BGP) during treatment of hyperthyroidism and hypothyroidism. A longitudinal study.","date":"1991","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/1864560","citation_count":18,"is_preprint":false},{"pmid":"26284027","id":"PMC_26284027","title":"Hepatic CEACAM1 Over-Expression Protects Against Diet-Induced Fibrosis and Inflammation in White Adipose Tissue.","date":"2015","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26284027","citation_count":18,"is_preprint":false},{"pmid":"18843289","id":"PMC_18843289","title":"Cytokine-induced CEACAM1 expression on keratinocytes is characteristic for psoriatic skin and contributes to a prolonged lifespan of neutrophils.","date":"2008","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18843289","citation_count":17,"is_preprint":false},{"pmid":"17692355","id":"PMC_17692355","title":"Heparan sulfate is a binding molecule but not a receptor for CEACAM1-independent infection of murine coronavirus.","date":"2007","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/17692355","citation_count":17,"is_preprint":false},{"pmid":"29843817","id":"PMC_29843817","title":"BGP: identifying gene-specific branching dynamics from single-cell data with a branching Gaussian process.","date":"2018","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/29843817","citation_count":16,"is_preprint":false},{"pmid":"11922629","id":"PMC_11922629","title":"Secreted CEACAM1 splice variants in rat cell lines and in vivo in rat serum.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11922629","citation_count":16,"is_preprint":false},{"pmid":"19358828","id":"PMC_19358828","title":"Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19358828","citation_count":16,"is_preprint":false},{"pmid":"15364113","id":"PMC_15364113","title":"Retinoic acid treated HL60 cells express CEACAM1 (CD66a) and phagocytose Neisseria gonorrhoeae.","date":"2004","source":"FEMS immunology and medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15364113","citation_count":15,"is_preprint":false},{"pmid":"37479191","id":"PMC_37479191","title":"T Cell CEACAM1-TIM-3 Crosstalk Alleviates Liver Transplant Injury in Mice and Humans.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37479191","citation_count":15,"is_preprint":false},{"pmid":"35495686","id":"PMC_35495686","title":"Identification of BgP, a Cutinase-Like Polyesterase From a Deep-Sea Sponge-Derived Actinobacterium.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35495686","citation_count":15,"is_preprint":false},{"pmid":"27464654","id":"PMC_27464654","title":"CEACAM1 is overexpressed in oral tumors and related to tumorigenesis.","date":"2016","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/27464654","citation_count":15,"is_preprint":false},{"pmid":"29158428","id":"PMC_29158428","title":"The Borrelia burgdorferi Glycosaminoglycan Binding Protein Bgp in the B31 Strain Is Not Essential for Infectivity despite Facilitating Adherence and Tissue Colonization.","date":"2018","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29158428","citation_count":15,"is_preprint":false},{"pmid":"29436278","id":"PMC_29436278","title":"Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.","date":"2018","source":"Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/29436278","citation_count":15,"is_preprint":false},{"pmid":"12108545","id":"PMC_12108545","title":"Clustering-induced signaling of CEACAM1 in PC12 cells.","date":"2002","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12108545","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48979,"output_tokens":8291,"usd":0.135651},"stage2":{"model":"claude-opus-4-6","input_tokens":12199,"output_tokens":4763,"usd":0.270105},"total_usd":0.405756,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"CEACAM1 forms a heterodimer with TIM-3 via their membrane-distal IgV-like N-terminal domains, both in cis (facilitating TIM-3 maturation and cell surface expression) and in trans (mediating inhibitory signaling); CEACAM1 is required for TIM-3 inhibitory function in T cells\",\n      \"method\": \"Biochemical co-immunoprecipitation, biophysical binding assays, X-ray crystallography, mouse adoptive transfer colitis model, T cell-specific CEACAM1 deletion/reconstitution\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — X-ray crystallography plus multiple biochemical methods plus in vivo genetic rescue in a single study\",\n      \"pmids\": [\"25363763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CEACAM1 isoforms with long cytoplasmic domain inhibit T cell activation (proliferation, cytokine production, allogeneic reactivity) through ITIMs in the cytoplasmic domain that recruit SHP1; conditional T cell deletion of CEACAM1 enhances TCR-CD3 signaling\",\n      \"method\": \"CEACAM1 overexpression and conditional deletion in T cells, in vitro T cell assays, mouse models of delayed-type hypersensitivity and inflammatory bowel disease, ITIM mutagenesis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype plus ITIM mutagenesis and SHP1 dependence across multiple assays\",\n      \"pmids\": [\"17081782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The cytoplasmic domain of CEACAM1 associates with pp60c-src; the recombinant cytoplasmic domain is both a substrate and binding partner of pp60c-src in vitro, and tyrosine-containing phosphopeptides from the cytoplasmic domain activate pp60c-src kinase activity\",\n      \"method\": \"Co-immunoprecipitation from granulocytes and HT29 cells, in vitro kinase assay with recombinant cytoplasmic domain\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution and co-IP from endogenous sources with orthogonal methods\",\n      \"pmids\": [\"7478590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Phosphorylated Tyr488 of CEACAM1 binds the SH2 domain of Shc, sequestering Shc from the insulin receptor/Grb2 complex and down-regulating the Ras/MAP kinase mitogenesis pathway and PI3K/Akt pathway\",\n      \"method\": \"Co-immunoprecipitation in NIH 3T3 cells, GST pull-down assays, Shc SH2 domain overexpression rescue experiments, MAP kinase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — GST pull-down plus co-IP plus functional rescue with multiple pathway readouts\",\n      \"pmids\": [\"11694516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CEACAM1 regulates insulin clearance in liver; phosphorylation of CEACAM1 on Ser503 is required for receptor-mediated insulin endocytosis and degradation; dominant-negative S503A mutant transgenic mice show impaired insulin clearance and insulin resistance\",\n      \"method\": \"Transgenic mouse overexpressing phosphorylation-defective S503A CEACAM1 mutant in liver (L-SACC1 model), metabolic phenotyping\",\n      \"journal\": \"Trends in endocrinology and metabolism: TEM\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo site-directed mutagenesis with defined metabolic phenotype in transgenic model\",\n      \"pmids\": [\"12128284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The cytoplasmic tail of CEACAM1 (BGPa) contains functional ITIMs; tyrosine Y459 within the ITIM is required for inhibitory signaling; CEACAM1 inhibitory signaling requires SHP-1 and SHP-2 phosphatases\",\n      \"method\": \"FcγRIIB-BGPa chimeric receptor expressed in DT40 B cells, calcium influx assays, Y459F mutagenesis, SHP-1/SHP-2 mutant DT40 cells\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus defined phosphatase-deficient cell lines with functional assay\",\n      \"pmids\": [\"11493628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Bacterial engagement of CEACAM1 (via M. catarrhalis UspA1 or N. meningitidis Opa proteins) triggers tyrosine phosphorylation of CEACAM1 ITIMs, recruits SHP-1, and inhibits TLR2-initiated NF-κB signaling and PI3K-Akt pathway in pulmonary epithelial cells\",\n      \"method\": \"Bacterial infection of primary pulmonary epithelial cells, phosphorylation assays, SHP-1 recruitment assays, NF-κB and Akt pathway readouts\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays including pathway endpoint readouts with mechanistic detail in primary cells\",\n      \"pmids\": [\"18836450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LPS-activated neutrophils form a complex of TLR4, phospho-Syk, and phospho-CEACAM1; this complex recruits SHP-1 via CEACAM1 ITIMs to inhibit IL-1β production by the inflammasome; ITIM mutation abolishes this regulation\",\n      \"method\": \"Co-immunoprecipitation, Ceacam1−/− neutrophils, in vivo bone marrow reconstitution with ITIM-mutant CEACAM1, Syk inhibitors, RNAi knockdown\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complex reconstitution in vivo plus ITIM mutagenesis plus knockout rescue with multiple orthogonal methods\",\n      \"pmids\": [\"22496641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolysis via trans-homophilic CEACAM1 interactions; co-engagement of NKG2D and CEACAM1 causes biochemical association of these receptors and CEACAM1-recruited SHP-1 dephosphorylates Vav1, blocking downstream cytolytic signaling\",\n      \"method\": \"NK cell cytotoxicity assays, co-immunoprecipitation, phosphorylation assays for Vav1, mouse and human NK cells with IL-2-induced CEACAM1 expression\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor co-immunoprecipitation plus downstream signaling readout plus trans-interaction requirement established in both mouse and human NK cells\",\n      \"pmids\": [\"23696226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CEACAM1 is a substrate of EGFR; upon phosphorylation, CEACAM1 reduces EGFR-mediated cell growth by binding to and sequestering Shc, uncoupling EGFR from the Ras/MAPK pathway\",\n      \"method\": \"Co-immunoprecipitation in transfected Cos-7 and MCF-7 cells, transgenic L-SACC1 mice with phosphorylation-defective CEACAM1 mutant, MAPK activity assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus in vivo transgenic model with mechanistic pathway dissection\",\n      \"pmids\": [\"15467833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CEACAM1-L cytoplasmic domain directly binds filamin A; when co-expressed, CEACAM1-L and filamin A drastically reduce cell migration and scattering compared with either protein alone; this interaction reduces RalA binding to filamin A and decreases focal adhesion turnover\",\n      \"method\": \"Yeast two-hybrid screen, surface plasmon resonance, affinity precipitation, migration/scattering assays in melanoma cells, focal adhesion assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding confirmed by SPR plus functional rescue experiments with mechanistic detail\",\n      \"pmids\": [\"16291724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CEACAM1-mediated delay of spontaneous and Fas ligand-induced granulocyte apoptosis requires tyrosine phosphorylation of CEACAM1-L, its association with SHP-1, and activation of Erk1/2; caspase-3 is also involved\",\n      \"method\": \"DNA fragmentation assays, annexin V staining, CEACAM1-Fc constructs, CEACAM1-specific Fab fragments, co-immunoprecipitation, kinase activation assays in rat granulocytes\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with mechanistic signaling detail in a single lab study\",\n      \"pmids\": [\"15909305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Homotypic CEACAM1 interactions between melanoma cells and NK cells provide MHC class I-independent inhibition of NK cytotoxicity; inhibitory strength correlates with CEACAM1 expression levels\",\n      \"method\": \"NK cell cytotoxicity assays, redirected lysis experiments, CD66a transfectants of 721.221 cells, NK clones from melanoma patients\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular phenotype with dose-response relationship, transfectant and patient-derived NK cell validation\",\n      \"pmids\": [\"11884449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tumor cell-associated CEACAM1 causes intracellular retention of NKG2D ligands in mouse and human tumor cells; CEACAM1-silenced tumor cells display more cell surface NKG2D ligands and greater sensitivity to NK cell-mediated cytolysis in vitro and rejection in vivo\",\n      \"method\": \"CEACAM1 silencing in tumor cells, flow cytometry for NKG2D ligand surface expression, NK cytotoxicity assays, in vivo tumor rejection\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined molecular and cellular phenotypes in vitro and in vivo\",\n      \"pmids\": [\"22143889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM1 is required for recruiting Lck into the TCR complex to form an efficient immunological synapse in CD8+ T cells; absence of CEACAM1 limits antiviral CD8+ T cell activation; anti-CEACAM1 antibody stabilizes Lck in the immunological synapse and prevents CD8+ T cell exhaustion\",\n      \"method\": \"LCMV infection model in Ceacam1−/− mice, immunological synapse imaging, Lck co-immunoprecipitation, anti-CEACAM1 antibody treatment, human virus-specific CD8+ T cell proliferation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus mechanistic co-IP plus antibody intervention replicated in mouse and human\",\n      \"pmids\": [\"29967450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CEACAM1 promotes B cell survival via the BTK/Syk/NF-κB signaling axis; Ceacam1−/− mice have reduced B cell survival and fail to mount protective neutralizing antibody responses during cytopathic viral infection\",\n      \"method\": \"Ceacam1−/− mice, VSV infection model, flow cytometry for B cell survival, BTK/Syk/NF-κB pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined survival pathway and in vivo infectious challenge\",\n      \"pmids\": [\"25692415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CEACAM1 expression enhances melanoma cell invasion and migration in a manner dependent on Tyr-488 in the cytoplasmic domain and on αvβ3 integrin; integrin β3 induces CEACAM1 upregulation in melanocytic cells\",\n      \"method\": \"Stable CEACAM1 transfection in melanocytic/melanoma cells, invasion/migration assays, anti-CEACAM antibody blockade, RGD peptide inhibition, Tyr-488 mutagenesis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus multiple functional assays plus antibody and peptide inhibition\",\n      \"pmids\": [\"15509546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CEACAM1 negatively regulates platelet-collagen interactions via GPVI/FcR-γ-chain signaling; Ceacam1−/− platelets show enhanced collagen-mediated aggregation and granule secretion; SHP-1 recruitment through CEACAM1 ITIMs mediates this inhibitory function; ceacam1−/− mice form larger, more stable thrombi in vivo\",\n      \"method\": \"Ceacam1−/− mice, platelet aggregation assays, CRP-stimulation, intravital microscopy of FeCl3-injured mesenteric arterioles, GPVI depletion rescue, pulmonary thromboembolism model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple in vitro and in vivo functional assays and epistasis via GPVI depletion\",\n      \"pmids\": [\"19008452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CEACAM1 long isoform (CEACAM1-4L) downregulates cell surface NKG2D ligands (MICA, ULBP2) by enhanced shedding, promoting immune escape; whereas CEACAM1-3S isoform upregulates NKG2D ligands and sensitizes melanoma cells to NK lysis — demonstrating isoform-specific immunomodulatory mechanisms\",\n      \"method\": \"Isoform-specific knockdown and overexpression in melanoma cells, flow cytometry for NKG2D ligand surface expression, NK cytotoxicity assays, in vivo xenograft model, patient survival analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific KD/OE with defined molecular phenotype but single lab\",\n      \"pmids\": [\"25744717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fusobacterium nucleatum binds and activates CEACAM1 via its surface protein CbpF (trimeric autotransporter adhesin), leading to inhibition of T and NK cell activities; CbpF-specific mutants abolish CEACAM1 binding and T cell inhibition\",\n      \"method\": \"F. nucleatum mutants lacking CbpF and other trimeric autotransporter adhesins, CEACAM1 binding assays, functional T cell and NK cell inhibition assays, anti-CEACAM1 N-domain antibody blocking\",\n      \"journal\": \"Oncoimmunology / Frontiers in cellular and infection microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific bacterial mutants plus functional immune assays plus antibody blocking replicated across two studies\",\n      \"pmids\": [\"31069151\", \"34336716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DC-SIGN binds CEACAM1 on neutrophils via Lewis x glycan moieties specifically expressed on neutrophil-derived CEACAM1; both DC-SIGN-CEACAM1 and DC-SIGN-Mac-1 interactions are required to establish DC-neutrophil cellular contact\",\n      \"method\": \"CEACAM1 binding assays with DC-SIGN, fucosidase treatment, antibody blocking, co-culture DC-neutrophil interaction assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding plus fucosidase abrogation plus functional co-culture assay\",\n      \"pmids\": [\"16246332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CEACAM1 N-glycans from human granulocytes carry Lewis x epitopes; MALDI-TOF MS and sequential exoglycosidase digestion characterized multiple Lewis x glycan structures with alpha(1-3,4) fucose linkages on CEACAM1\",\n      \"method\": \"Immunoaffinity purification of CEACAM1, Lewis x-specific antibody binding, fucosidase III treatment, MALDI-TOF MS with sequential exoglycosidase digestion\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS structural characterization plus enzymatic digestion validation\",\n      \"pmids\": [\"15317738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CEACAM1 long isoform increases melanoma cell proliferation via upregulation of Sox-2; this effect requires the full-length long cytoplasmic tail and is not reversed by CEACAM1-blocking antibody, indicating it is not mediated by homophilic interactions\",\n      \"method\": \"CEACAM1 knockdown and overexpression of selective variants/truncation mutants, in vitro and in vivo proliferation assays, Sox-2 expression analysis, CEACAM1-blocking antibody treatment\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structure-function analysis with truncation mutants and downstream target identification\",\n      \"pmids\": [\"24931667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CEACAM6 expressed on cancer cells inhibits T cell antitumor activity by binding CEACAM1 on activated T cells (trans heterophilic interaction); blocking CEACAM6 with antibody BAY 1834942 reactivates T cell responses\",\n      \"method\": \"Co-culture experiments with T cells and solid cancer cells, CEACAM6-CEACAM1 interaction assays, cytokine and killing assays, comparison with PD-1/PD-L1/TIM-3 checkpoint blockade\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — blocking antibody plus functional T cell assays in co-culture establishing CEACAM6-CEACAM1 trans interaction requirement\",\n      \"pmids\": [\"35141051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CEACAM1 clustering by surface ligation induces rapid tyrosine dephosphorylation, reduced association with SHP2, translocation to actin cytoskeleton, and activation of ERK1/2 MAPK in PC12 cells\",\n      \"method\": \"Antibody-induced CEACAM1 clustering, phosphorylation assays, co-immunoprecipitation with SHP2, detergent fractionation for cytoskeleton association, ERK1/2 activation assay\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal signaling assays in a single study\",\n      \"pmids\": [\"12108545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Soluble CEACAM8 binds CEACAM1 on pulmonary epithelial cells and inhibits TLR2-dependent NF-κB signaling via CEACAM1 ITIM phosphorylation and SHP-1 recruitment, suppressing PI3K-Akt pathway activation\",\n      \"method\": \"Recombinant CEACAM8-Fc binding to CEACAM1-positive epithelial cells, TLR2 stimulation assays, ITIM phosphorylation assays, SHP-1 co-immunoprecipitation, Akt pathway readouts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct heterophilic binding plus multiple signaling pathway assays; partially recapitulates earlier CEACAM1-SHP1 mechanism\",\n      \"pmids\": [\"24743304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CEACAM1 regulates the LPS-driven IL-6 fever response through monocyte RP105 receptor signaling; CEACAM1 recruits SHP-1 to sequester phospho-VAV1 and β-actin from RP105, negatively regulating this pathway; Ceacam1−/− mice over-produce IL-6 in response to LPS\",\n      \"method\": \"Ceacam1−/− mice LPS challenge, in vitro monocyte stimulation, RP105 complex co-immunoprecipitation, SHP-1 recruitment assays, PET imaging with 64Cu-LPS\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with in vivo phenotype plus co-IP complex identification\",\n      \"pmids\": [\"30674283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HIF-1α controls alternative splicing of CEACAM1 toward the short cytoplasmic isoform (Ceacam1-S) through transcriptional regulation of the Ptbp1 promoter; Ceacam1-S protects hepatocytes from hypoxia-induced loss of adhesion by repressing the ASK1/p-p38 cell death pathway\",\n      \"method\": \"Chromatin immunoprecipitation assays identifying HIF-1α binding to Ptbp1 promoter, luciferase reporter assays, adenoviral Ceacam1-S transfection in KO hepatocytes, morpholino-induced Ceacam1-S splicing, DMOG prolyl hydroxylase inhibitor treatment, in vitro and in vivo mouse models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP-confirmed transcription factor binding plus functional reconstitution plus pharmacologic intervention with defined pathway readout\",\n      \"pmids\": [\"37531413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The long cytoplasmic isoform of CEACAM1 (CC1-L) in neutrophils determines susceptibility to NETosis by regulating the S1P-S1PR2/S1PR3 axis and autophagy signaling; ablation of CC1-L aggravates hepatic ischemia-reperfusion injury by promoting NET formation\",\n      \"method\": \"Mouse OLT model with isoform-specific CC1-L ablation, NETosis assays, S1P-S1PR2/S1PR3 axis analysis, autophagy signaling assays, human liver transplant biopsy analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific genetic ablation in mouse OLT model with defined pathway and validated in human clinical samples\",\n      \"pmids\": [\"36719377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CD66a (CEACAM1) and CD66b are the major galectin-3 receptors on human neutrophils; both proteins are stored in gelatinase and specific granules and mobilized to the cell surface upon activation\",\n      \"method\": \"Galectin-3-Sepharose affinity chromatography of neutrophil granule proteins, immunoblotting, lactose elution, subcellular fractionation, differentiated HL-60 cells lacking specific granules\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — affinity chromatography identification plus subcellular localization confirmed by granule fractionation\",\n      \"pmids\": [\"10553088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM1 expression in hepatocytes protects against ischemia-reperfusion injury by suppressing ASK1/p-p38 upregulation, reducing ROS induction and HMGB1 translocation; CC1-deficient livers show augmented cold stress-triggered ASK1/p-p38 signaling\",\n      \"method\": \"CC1-KO mouse OLT model, ASK1 inhibition rescue, ROS and HMGB1 assays, bone marrow-derived macrophage co-culture, siRNA ASK1 silencing in hepatocyte cultures, human liver biopsy correlation\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus ASK1 inhibitor epistasis plus in vitro cell culture mechanistic validation plus human correlation\",\n      \"pmids\": [\"32027621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM1 deficiency causes eNOS depalmitoylation and subcellular redistribution, altered endothelial glycocalyx (through repression of glycocalyx-degrading enzymes), increased leukocyte-endothelial adhesion, and age-dependent modulation of endothelial barrier function through β-catenin and caveolin-1 phosphorylation\",\n      \"method\": \"Ceacam1−/− mice, eNOS localization by immunofluorescence, glycocalyx assays, leukocyte adhesion assays, β-catenin/caveolin-1 phosphorylation Western blot, TNF-α stimulation\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model with multiple molecular mechanism readouts but a single lab study\",\n      \"pmids\": [\"29746166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Forced hepatic CEACAM1 overexpression in mice prevents high-fat diet-induced hyperinsulinemia, insulin resistance, and hepatic lipid accumulation partly by increasing hepatic β-fatty acid oxidation and energy expenditure\",\n      \"method\": \"Liver-specific inducible CEACAM1 expression (L-CC1) transgenic mice, high-fat diet metabolic challenge, glucose/insulin tolerance tests, fatty acid oxidation assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function transgenic model with defined metabolic phenotype and mechanistic pathway (β-oxidation)\",\n      \"pmids\": [\"25972571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CEACAM1 or CEACAM5 expression in AZ-521 cells (which lack CEACAMs) restores H. pylori type IV secretion system-mediated CagA translocation and phosphorylation, identifying CEACAM1 as a T4SS receptor for CagA injection\",\n      \"method\": \"CEACAM1/CEACAM5/CEACAM6 transfection into AZ-521 cells, H. pylori infection, CagA translocation and phosphorylation assays, vinculin/cortactin dephosphorylation assays\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function reconstitution with receptor specificity established (CEACAM1/5 but not 6) plus downstream effector validation\",\n      \"pmids\": [\"30321907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cross-linking of CEACAM1 on intestinal intraepithelial lymphocytes (iIEL) with mAbs recognizing the N domain inhibits anti-CD3-directed and LAK cytolytic activity; the N domain mediates inhibitory signaling\",\n      \"method\": \"Expression cloning identifying CEACAM1 as mAb antigen, Fc fusion protein binding studies, functional cytolysis inhibition assays with iIEL\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — expression cloning plus functional inhibition assay with domain identification\",\n      \"pmids\": [\"10415036\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CEACAM1 is a multifunctional transmembrane glycoprotein that signals primarily through ITIM-mediated recruitment of SHP-1/SHP-2 phosphatases upon tyrosine phosphorylation of its long cytoplasmic domain, thereby inhibiting T cell, NK cell, neutrophil, platelet, and B cell activation; it also forms cis and trans heterodimers with TIM-3 to regulate T cell tolerance, associates with pp60c-src and recruits Lck into the immunological synapse, sequesters Shc to downregulate Ras/MAPK and PI3K/Akt mitogenic signaling downstream of insulin and EGF receptors, binds filamin A to modulate cell migration, regulates alternative splicing of its own isoforms through HIF-1α/Ptbp1 to protect against hepatic ischemia-reperfusion injury, and serves as a bacterial receptor (for Neisseria Opa proteins, H. pylori CagA T4SS, and Fusobacterium CbpF) that pathogens exploit for immune evasion.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CEACAM1 is a multifunctional immunoregulatory transmembrane glycoprotein that broadly dampens activation signals in T cells, NK cells, neutrophils, platelets, and B cells while simultaneously modulating hepatic insulin clearance, cell migration, and pathogen entry. Its inhibitory signaling proceeds through ITIM-dependent recruitment of SHP-1 and SHP-2 phosphatases upon tyrosine phosphorylation of the long cytoplasmic domain (Tyr459/Tyr488), which dephosphorylates downstream effectors such as Vav1, uncouples Shc from receptor tyrosine kinases (insulin receptor, EGFR) to attenuate Ras/MAPK and PI3K/Akt signaling, and suppresses TLR-initiated NF-κB activation [PMID:11493628, PMID:11694516, PMID:18836450, PMID:23696226]. CEACAM1 forms obligate cis and trans heterodimers with TIM-3 through its N-terminal IgV domain, is required for TIM-3 surface expression and T cell inhibitory function, and recruits Lck into the immunological synapse of CD8⁺ T cells, positioning it as a dual checkpoint regulator [PMID:25363763, PMID:29967450]. The N-terminal domain also serves as a receptor exploited by bacterial adhesins—Neisseria Opa proteins, H. pylori CagA type IV secretion system, and Fusobacterium nucleatum CbpF—to trigger ITIM-mediated immune suppression or facilitate virulence factor injection [PMID:18836450, PMID:30321907, PMID:31069151]. Isoform-specific functions are regulated by HIF-1α/Ptbp1-controlled alternative splicing: the short isoform protects hepatocytes from hypoxia-induced ASK1/p-p38 death signaling, while the long isoform in neutrophils restrains NETosis via S1P receptor signaling, collectively governing hepatic ischemia-reperfusion injury outcomes [PMID:37531413, PMID:36719377].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying the first intracellular signaling partner of CEACAM1 established that it is a substrate and activator of pp60c-src, positioning it as a phosphotyrosine-based signaling receptor rather than a passive adhesion molecule.\",\n      \"evidence\": \"Co-immunoprecipitation from granulocytes/HT29 cells and in vitro kinase assays with recombinant cytoplasmic domain\",\n      \"pmids\": [\"7478590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase(s) responsible for CEACAM1 phosphorylation in vivo not resolved\", \"Functional consequence of Src activation by CEACAM1 not determined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that cross-linking the CEACAM1 N-domain inhibits cytolytic activity of intestinal intraepithelial lymphocytes established that CEACAM1 functions as an inhibitory receptor in the immune system, with domain-level specificity.\",\n      \"evidence\": \"Expression cloning, Fc fusion binding, and functional cytolysis inhibition assays with iIEL\",\n      \"pmids\": [\"10415036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling mechanism of inhibition not identified\", \"Whether ITIM phosphatase recruitment mediates the effect was not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of functional ITIMs in the cytoplasmic tail and demonstration that SHP-1/SHP-2 are the required effector phosphatases provided the core molecular mechanism of CEACAM1 inhibitory signaling, while parallel work showed phospho-Tyr488 sequesters Shc to attenuate Ras/MAPK and PI3K/Akt pathways downstream of insulin receptor.\",\n      \"evidence\": \"FcγRIIB-CEACAM1 chimeras in DT40 B cells with SHP-1/SHP-2-deficient lines and Y459F mutagenesis; GST pull-downs and co-IP in NIH 3T3 cells with MAPK activity rescue\",\n      \"pmids\": [\"11493628\", \"11694516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SHP-1 vs SHP-2 has non-redundant roles in different cell types was unclear\", \"Structural basis of ITIM-SHP interaction not determined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that trans-homophilic CEACAM1 engagement inhibits NK cytotoxicity independently of MHC class I revealed a new immune evasion axis; concurrently, Ser503 phosphorylation was shown to be required for hepatic insulin clearance, establishing CEACAM1 as a metabolic regulator.\",\n      \"evidence\": \"NK redirected lysis assays with CEACAM1 transfectants; L-SACC1 transgenic mice with S503A mutant metabolic phenotyping\",\n      \"pmids\": [\"11884449\", \"12128284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between Ser503 phosphorylation and receptor-mediated endocytosis machinery not identified\", \"Ligand on tumor cells engaging CEACAM1 trans-homophilic interaction not fully characterized\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing CEACAM1 is an EGFR substrate that sequesters Shc to uncouple EGFR from MAPK signaling unified the Shc-sequestration mechanism across receptor tyrosine kinases, while Tyr488-dependent enhancement of melanoma invasion revealed context-dependent pro-migratory roles.\",\n      \"evidence\": \"Co-IP in Cos-7/MCF-7 cells plus L-SACC1 transgenic MAPK assays; CEACAM1 transfection in melanoma cells with Y488 mutagenesis and integrin blocking\",\n      \"pmids\": [\"15467833\", \"15509546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same Tyr488-Shc interaction mediates growth inhibition in epithelial cells but invasion in melanoma was not reconciled\", \"Integrin β3–CEACAM1 crosstalk mechanism not elucidated\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Direct binding of CEACAM1-L to filamin A established a structural link to the actin cytoskeleton, explaining how CEACAM1 reduces cell migration by displacing RalA from filamin A and decreasing focal adhesion turnover.\",\n      \"evidence\": \"Yeast two-hybrid, SPR, affinity precipitation, and migration/scattering assays in melanoma cells\",\n      \"pmids\": [\"16291724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether filamin A interaction is regulated by CEACAM1 phosphorylation state was not tested\", \"In vivo relevance of the CEACAM1–filamin A complex not demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Conditional T cell-specific deletion of CEACAM1 established it as a bona fide T cell inhibitory receptor in vivo, with ITIM-dependent SHP-1 recruitment required for suppression of TCR-CD3 signaling, proliferation, and cytokine production.\",\n      \"evidence\": \"Conditional KO T cells, in vitro T cell assays, mouse DTH and IBD models, ITIM mutagenesis\",\n      \"pmids\": [\"17081782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of SHP-1 vs SHP-2 in T cell inhibition not delineated\", \"Whether CEACAM1 inhibitory function is ligand-dependent or constitutive in T cells not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Bacterial exploitation of CEACAM1 was mechanistically defined: Neisseria/Moraxella Opa/UspA1 engagement triggers ITIM phosphorylation and SHP-1 recruitment to suppress TLR2-NF-κB and PI3K-Akt signaling, while CEACAM1 was separately shown to be an ITIM-dependent inhibitor of platelet GPVI-collagen signaling governing thrombus formation in vivo.\",\n      \"evidence\": \"Primary pulmonary epithelial infection with bacterial mutants and pathway readouts; Ceacam1−/− platelet aggregation, intravital microscopy, and GPVI depletion rescue\",\n      \"pmids\": [\"18836450\", \"19008452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether bacterial engagement activates a distinct downstream program beyond canonical ITIM-SHP1 not known\", \"Structural basis of Opa–CEACAM1 N-domain interaction not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery that CEACAM1 forms a ternary complex with TLR4 and phospho-Syk in neutrophils to recruit SHP-1 and suppress inflammasome-driven IL-1β production expanded its inhibitory role to innate immune danger signaling.\",\n      \"evidence\": \"Co-IP in Ceacam1−/− neutrophils, in vivo bone marrow reconstitution with ITIM-mutant CEACAM1, Syk inhibitors, RNAi\",\n      \"pmids\": [\"22496641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEACAM1 directly interacts with NLRP3 inflammasome components not tested\", \"Upstream signal triggering CEACAM1–Syk association not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The NK cell inhibitory mechanism was refined: trans-homophilic CEACAM1 ligation recruits SHP-1 to dephosphorylate Vav1, directly blocking NKG2D cytolytic signaling, identifying a specific phosphatase substrate mediating immune evasion.\",\n      \"evidence\": \"Co-IP and phospho-Vav1 assays in IL-2-activated mouse and human NK cells plus cytotoxicity assays\",\n      \"pmids\": [\"23696226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other activating receptor pathways beyond NKG2D are similarly regulated not tested\", \"Structural determinants of CEACAM1–NKG2D co-association not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural and functional evidence that CEACAM1 heterodimerizes with TIM-3 via N-terminal IgV domains in both cis and trans, and is required for TIM-3 maturation, surface expression, and inhibitory function, established a new paradigm of immune checkpoint cooperativity; simultaneously, isoform-specific regulation of NKG2D ligand shedding was demonstrated.\",\n      \"evidence\": \"X-ray crystallography, co-IP, biophysical binding, T cell-specific CEACAM1 KO/reconstitution, adoptive transfer colitis; isoform-specific KD/OE with NK cytotoxicity and xenograft\",\n      \"pmids\": [\"25363763\", \"25744717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of cis vs trans dimer selectivity not fully resolved\", \"Signaling events downstream of CEACAM1–TIM-3 trans ligation not characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"CEACAM1 was shown to promote B cell survival via BTK/Syk/NF-κB signaling and to be required for protective antibody responses during viral infection, establishing a pro-survival function distinct from its canonical inhibitory role.\",\n      \"evidence\": \"Ceacam1−/− mice, VSV infection, B cell survival flow cytometry, BTK/Syk/NF-κB pathway analysis\",\n      \"pmids\": [\"25692415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CEACAM1 directly engages BTK/Syk or acts indirectly not determined\", \"Mechanism reconciling pro-survival B cell function with inhibitory signaling in other lymphocytes not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CEACAM1 was found to recruit Lck into the immunological synapse of CD8+ T cells, with its absence limiting antiviral T cell activation and antibody-mediated CEACAM1 stabilization preventing exhaustion—revealing a co-stimulatory dimension alongside its inhibitory functions; separately, CEACAM1 was identified as a receptor for H. pylori CagA T4SS injection.\",\n      \"evidence\": \"LCMV infection in Ceacam1−/− mice, Lck co-IP, synapse imaging, anti-CEACAM1 antibody in mouse/human; CEACAM1 transfection into AZ-521 cells restoring CagA translocation\",\n      \"pmids\": [\"29967450\", \"30321907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CEACAM1 simultaneously recruits Lck (activating) and SHP-1 (inhibitory) is mechanistically unresolved\", \"Whether CagA translocation requires CEACAM1 ITIM signaling not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Fusobacterium nucleatum CbpF was identified as a CEACAM1 ligand that triggers T and NK cell inhibition, extending the bacterial immune evasion paradigm to a tumor-associated pathogen; CEACAM1 was also shown to regulate monocyte IL-6 fever response via SHP-1 sequestration of VAV1 from RP105.\",\n      \"evidence\": \"F. nucleatum CbpF mutants with CEACAM1 binding/T cell assays; Ceacam1−/− mice LPS challenge with RP105 co-IP\",\n      \"pmids\": [\"31069151\", \"34336716\", \"30674283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CbpF-CEACAM1 interaction contributes to Fusobacterium-associated colorectal cancer immune evasion in vivo not demonstrated\", \"RP105–CEACAM1 interaction awaits structural characterization\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Isoform-specific functions were mechanistically grounded: HIF-1α transcriptionally induces Ptbp1 to splice CEACAM1 toward the short isoform, which protects hepatocytes from ASK1/p-p38 death signaling during hypoxia; conversely, the long isoform in neutrophils restrains NETosis via S1P–S1PR2/3 and autophagy, with its ablation worsening hepatic ischemia-reperfusion injury.\",\n      \"evidence\": \"ChIP for HIF-1α on Ptbp1 promoter, adenoviral Ceacam1-S reconstitution, morpholino splicing, DMOG treatment; isoform-specific CC1-L ablation in mouse OLT with NETosis/S1P pathway assays and human biopsy validation\",\n      \"pmids\": [\"37531413\", \"36719377\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Ptbp1-mediated splicing regulation occurs in non-hepatic tissues not tested\", \"Direct molecular target of CEACAM1-S that represses ASK1 not identified\", \"How CEACAM1-L regulates S1P receptor balance mechanistically remains unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which CEACAM1 simultaneously mediates inhibitory (SHP-1/SHP-2 recruitment) and activating (Lck recruitment, B cell survival via BTK/Syk) functions in different immune contexts, and how isoform balance is dynamically regulated beyond hepatic ischemia, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model reconciling inhibitory vs co-stimulatory CEACAM1 signaling across cell types\", \"Structural basis for isoform-specific partner selectivity not determined\", \"In vivo therapeutic window for checkpoint blockade of CEACAM1 vs CEACAM1–TIM-3 axis not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 6, 7, 8, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 10, 14]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [6, 19, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 12, 14, 17, 20]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [10, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 5, 6, 7, 8, 14, 15, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 9, 17, 24]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 12, 20, 23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 32]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 27, 30]}\n    ],\n    \"complexes\": [\n      \"CEACAM1–TIM-3 heterodimer\",\n      \"CEACAM1–TLR4–Syk complex\",\n      \"CEACAM1–filamin A complex\"\n    ],\n    \"partners\": [\n      \"TIM-3\",\n      \"SHP-1\",\n      \"SHP-2\",\n      \"SRC\",\n      \"LCK\",\n      \"FLNA\",\n      \"SHC1\",\n      \"CEACAM6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}